MedTrace Logo

Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies

NCT01266265 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1333

Last updated 2016-02-17

Study results available
· View outcomes & findings →

Summary

A surveillance of respiratory tract related adverse events in patients treated with Tyvaso®(treprostinil) Inhalation Solution versus other FDA approved therapies

Conditions

Interventions

DRUG

inhaled prostacyclin

Tyvaso

DRUG

inhaled prostacyclin

As prescribed by the physician

DRUG

prostacyclin

As prescribed by the physician

DRUG

subcutaneous and intravenous prostacyclin

As prescribed by physician

DRUG

oral ERA

As prescribed by physician

DRUG

oral PDE5 inhibitors

As prescribed by physician

Sponsors & Collaborators

  • United Therapeutics

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01266265 on ClinicalTrials.gov